Mutations in the Abl protein cause some leukaemias. The determination of its structure and the identification of Abl variants resistant to an anti-leukaemia drug reveal regions of the protein needed for its regulation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hantschel, O. et al. Cell 112, 845–857 (2003).
Nagar, B. et al. Cell 112, 859–871 (2003).
Azam, M., Latek, R. R. & Daley, G. Q. Cell 112, 831–843 (2003).
Superti-Furga, G. & Courtneidge, S. BioEssays 17, 321–330 (1995).
Smith, J. M. & Mayer, B. J. Front. Biosci. 7, d31–d42 (2002).
Mauro, M. J. & Druker, B. J. Curr. Opin. Oncol. 13, 3–7 (2001).
Nagar, B. et al. Cancer Res. 62, 4236–4243 (2002).
Schindler, T. et al. Science 289, 1938–1942 (2000).
McCormick, F. Nature 412, 281–282 (2001).
Mayer, B. J. Curr. Biol. 7, R295–R298 (1997).
Pluk, H., Dorey, K. & Superti-Furga, G. Cell 108, 247–259 (2002).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Courtneidge, S. Escape from inhibition. Nature 422, 827–828 (2003). https://doi.org/10.1038/422827a
Issue Date:
DOI: https://doi.org/10.1038/422827a
This article is cited by
-
Regulation of the c-Abl and Bcr–Abl tyrosine kinases
Nature Reviews Molecular Cell Biology (2004)
